Nosocomial Acinetobacter pneumonia

被引:48
作者
Luna, Carlos M. [1 ]
Aruj, Patricia K. [1 ]
机构
[1] Univ Buenos Aires, Hosp Clin, Dept Internal Med, Div Pulm Dis, Buenos Aires, DF, Argentina
关键词
Acinetobacter; nosocomial pneumonia; multi-drug resistant; ventilator-associated pneumonia;
D O I
10.1111/j.1440-1843.2007.01147.x
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Acinetobacter spp. (A. baumannii is the prevalent genomic species, but others may cause infection) has become an increasingly important cause of nosocomial pneumonia, particularly in mechanically ventilated patients (VAP). This organism has intrinsic resistance to some antimicrobials but easily acquires resistance to many others; Acinetobacter spp. can survive for long periods of time in the environment. All of these characteristics have contributed to protracted outbreaks associated with significant morbidity and mortality. High rates of colonization are found in debilitated hospitalized patients. Infecting or colonizing organisms in nosocomial infections are more likely to be from cross-transmission or from the hospital environment than from endogenous sources. VAP caused by Acinetobacter spp. is emerging as a prominent hospital complication. The incidence of this microorganism varies from site to site, but it is the second commonest aetiological agent among the gram-negative bacteria. Longer periods of hospitalization, longer time on mechanical ventilation and prior use of antibiotics are the recognized factors increasing the risk of VAP due to Acinetobacter spp. Treatment needs to clearly differentiate infection from colonization, and the agents with the most antimicrobial activity are imipenem/cilastatin, amikacin, colistin, ampicillin/sulbactam and tigecycline. Monotherapy can be adequate if the patient does not have significant comorbidities. Infection control procedures have a major role to play in preventing transmission of this microorganism. Emphasis on initial control measures should, however, be on strict isolation of infected or colonized patients to limit dissemination of outbreak strains in the environment. The variety of potential sources of contamination with Acinetobacter spp. in the hospital environment makes control of these outbreaks one of the more difficult challenges. Persistence of Acinetobacter spp. in the environment provides ample opportunities for contamination of patients and staff and may explain continuing long-term outbreaks.
引用
收藏
页码:787 / 791
页数:5
相关论文
共 50 条
  • [41] Nosocomial pneumonia -: The importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU
    Höffken, G
    Niederman, MS
    CHEST, 2002, 122 (06) : 2183 - 2196
  • [42] Pseudomonas aeruginosa Nosocomial Pneumonia: Impact of Pneumonia Classification
    Micek, Scott T.
    Kollef, Marin H.
    Torres, Antoni
    Chen, Catherine
    Rello, Jordi
    Chastre, Jean
    Antonelli, Massimo
    Welte, Tobias
    Clair, Bernard
    Ostermann, Helmut
    Calbo, Esther
    Wunderink, Richard
    Menichetti, Francesco
    Schramm, Garrett
    Menon, Vandana
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2015, 36 (10) : 1190 - 1197
  • [43] Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex
    Zheng, Jun-Yuan
    Huang, Shie-Shian
    Huang, Shu-Huan
    Ye, Jung-Jr
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2020, 53 (06) : 854 - 865
  • [44] Noninferiority Margin for Clinical Trials of Antibacterial Drugs for Nosocomial Pneumonia
    Sorbello, Alfred
    Komo, Scott
    Valappil, Thamban
    DRUG INFORMATION JOURNAL, 2010, 44 (02): : 165 - 176
  • [45] Diabetes mellitus as a risk factor for nosocomial pneumonia and associated mortality
    Vardakas, K. Z.
    Siempos, I. I.
    Falagas, M. E.
    DIABETIC MEDICINE, 2007, 24 (10) : 1168 - 1171
  • [46] Safety considerations of current drug treatment strategies for nosocomial pneumonia
    Ceccato, Adrian
    Di Giannatale, Pierluigi
    Nogas, Stefano
    Torres, Antoni
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (02) : 181 - 190
  • [47] Pharmacotherapy for Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia
    Segarra-Newnham, Marisel
    Church, Timothy J.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (12) : 1678 - 1687
  • [48] Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex
    Lin, Huang-Shen
    Lee, Ming-Hsun
    Cheng, Chun-Wen
    Hsu, Po-Chang
    Leu, Hsieh-Shong
    Huang, Ching-Tai
    Ye, Jung-Jr
    INFECTIOUS DISEASES, 2015, 47 (06) : 370 - 378
  • [49] Tigecycline in surgical infections and nosocomial pneumonia
    Bonatti, Hugo
    Janata, Oskar
    Sawyer, Robert G.
    EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA, 2008, 40 (04): : 196 - 197
  • [50] Nosocomial pneumonia. Prevention and diagnostic
    Perl, T.
    Quintel, M.
    ANAESTHESIST, 2011, 60 (03): : 236 - 242